Solid Biosciences Inc. (SLDB) stock
SLDBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$6.23−0.25 (-3.86%)
Close on Nov 17, 2026Market cap $668.01MP/E –Yield –
Solid Biosciences total assets
Total assets on the balance sheet at the end of each period.
Solid Biosciences's total assets was $420.58M at Jun 30, 2026. For fiscal 2025 it was $232.54M, up 23.3% from the year before. The highest annual figure on record is $260.25M in fiscal 2022.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $232.54M | +23.3% |
| FY2024 | Dec 31, 2024 | $188.66M | +14.4% |
| FY2023 | Dec 31, 2023 | $164.94M | -36.6% |
| FY2022 | Dec 31, 2022 | $260.25M | +12.0% |
| FY2021 | Dec 31, 2021 | $232.38M | +35.8% |
| FY2020 | Dec 31, 2020 | $171.17M | +65.4% |
| FY2019 | Dec 31, 2019 | $103.47M | -25.9% |
| FY2018 | Dec 31, 2018 | $139.60M | +83.2% |
| FY2017 | Dec 31, 2017 | $76.19M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $420.58M | +36.4% |
| Q1 FY2026 | Mar 31, 2026 | $422.89M | +23.0% |
| Q4 FY2025 | Dec 31, 2025 | $232.54M | +23.3% |
| Q3 FY2025 | Sep 30, 2025 | $273.91M | +29.3% |
| Q2 FY2025 | Jun 30, 2025 | $308.29M | +33.5% |
| Q1 FY2025 | Mar 31, 2025 | $343.90M | +38.3% |
| Q4 FY2024 | Dec 31, 2024 | $188.66M | +14.4% |
| Q3 FY2024 | Sep 30, 2024 | $211.83M | +14.7% |
| Q2 FY2024 | Jun 30, 2024 | $230.98M | +12.8% |
| Q1 FY2024 | Mar 31, 2024 | $248.69M | +8.3% |
| Q4 FY2023 | Dec 31, 2023 | $164.94M | -36.6% |
| Q3 FY2023 | Sep 30, 2023 | $184.73M | +0.1% |
| Q2 FY2023 | Jun 30, 2023 | $204.72M | -1.8% |
| Q1 FY2023 | Mar 31, 2023 | $229.59M | +10.6% |
| Q4 FY2022 | Dec 31, 2022 | $260.25M | +12.0% |
| Q3 FY2022 | Sep 30, 2022 | $184.47M | -25.9% |
| Q2 FY2022 | Jun 30, 2022 | $208.50M | -21.6% |
| Q1 FY2022 | Mar 31, 2022 | $207.56M | -27.2% |
| Q4 FY2021 | Dec 31, 2021 | $232.38M | +35.8% |
| Q3 FY2021 | Sep 30, 2021 | $248.99M | +514.5% |
| Q2 FY2021 | Jun 30, 2021 | $265.86M | +358.7% |
| Q1 FY2021 | Mar 31, 2021 | $285.28M | +285.7% |
| Q4 FY2020 | Dec 31, 2020 | $171.17M | +65.4% |
| Q3 FY2020 | Sep 30, 2020 | $40.52M | -69.1% |
| Q2 FY2020 | Jun 30, 2020 | $57.96M | -39.8% |
| Q1 FY2020 | Mar 31, 2020 | $73.96M | -38.5% |
| Q4 FY2019 | Dec 31, 2019 | $103.47M | -25.9% |
| Q3 FY2019 | Sep 30, 2019 | $130.93M | -16.5% |
| Q2 FY2019 | Jun 30, 2019 | $96.30M | -43.8% |
| Q1 FY2019 | Mar 31, 2019 | $120.23M | -36.5% |
| Q4 FY2018 | Dec 31, 2018 | $139.60M | +83.2% |
| Q3 FY2018 | Sep 30, 2018 | $156.81M | – |
| Q2 FY2018 | Jun 30, 2018 | $171.47M | – |
| Q1 FY2018 | Mar 31, 2018 | $189.24M | – |
| Q4 FY2017 | Dec 31, 2017 | $76.19M | – |
See a number that looks wrong?